Analysts Set Exelixis, Inc. (NASDAQ:EXEL) Target Price at $24.38

Share on StockTwits

Exelixis, Inc. (NASDAQ:EXEL) has been given a consensus recommendation of “Hold” by the twelve analysts that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $24.38.

EXEL has been the subject of several recent analyst reports. ValuEngine raised shares of Exelixis from a “sell” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research lowered shares of Exelixis from a “hold” rating to a “sell” rating and set a $19.00 target price for the company. in a research report on Thursday, October 3rd. Piper Jaffray Companies decreased their price target on shares of Exelixis from $45.00 to $35.00 in a report on Thursday, October 31st. BidaskClub downgraded Exelixis from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. Finally, Bank of America initiated coverage on Exelixis in a research note on Wednesday, November 13th. They issued a “buy” rating and a $22.00 price objective on the stock.

In other news, CEO Michael Morrissey sold 37,227 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $19.20, for a total value of $714,758.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CMO Gisela Schwab sold 30,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $17.87, for a total transaction of $536,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 144,894 shares of company stock valued at $2,539,716 over the last three months. 4.50% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC lifted its stake in shares of Exelixis by 107.5% in the third quarter. Virtu Financial LLC now owns 55,353 shares of the biotechnology company’s stock worth $979,000 after buying an additional 28,681 shares during the last quarter. Symmetry Partners LLC bought a new position in Exelixis in the third quarter worth $185,000. U S Global Investors Inc. boosted its stake in Exelixis by 139.1% during the second quarter. U S Global Investors Inc. now owns 53,359 shares of the biotechnology company’s stock worth $1,140,000 after buying an additional 31,047 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in shares of Exelixis during the 3rd quarter valued at about $1,804,000. Finally, Janus Henderson Group PLC grew its stake in shares of Exelixis by 390.8% in the 2nd quarter. Janus Henderson Group PLC now owns 159,966 shares of the biotechnology company’s stock valued at $3,418,000 after purchasing an additional 127,372 shares during the period. Institutional investors and hedge funds own 77.03% of the company’s stock.

Shares of Exelixis stock traded up $0.95 during trading on Friday, hitting $17.62. 184,030 shares of the stock traded hands, compared to its average volume of 2,574,346. The stock has a market cap of $5.05 billion, a P/E ratio of 12.33, a PEG ratio of 2.19 and a beta of 1.78. The company has a fifty day moving average price of $16.46 and a two-hundred day moving average price of $19.11. Exelixis has a twelve month low of $15.02 and a twelve month high of $25.31. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.80 and a current ratio of 6.89.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.12. Exelixis had a net margin of 64.05% and a return on equity of 25.55%. The firm had revenue of $271.70 million for the quarter, compared to analyst estimates of $228.17 million. During the same quarter last year, the firm earned $0.44 earnings per share. The company’s revenue for the quarter was up 20.5% on a year-over-year basis. On average, equities research analysts expect that Exelixis will post 0.97 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Recommended Story: Portfolio Manager

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.